ClinicalTrials.gg
DrugRead study by study

Alpelisib clinical trials

Also written BYL719, Piqray and VIJOICE.

studies test it
85
open now
15
in phase 3
8
first study started
2010
ClinicalTrials.gov finds 128 studies for Alpelisib. How that becomes 85 here

Every study that search finds has been read, to see whether and how it gives Alpelisib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 128Found by its intervention search · See all 128 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 109 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −5
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 123Give Alpelisib to participants
  4. −16Observe patients on it, or give it outside a trial
  5. −3Compare another treatment with it
  6. −19Give it beside what is tested
  7. 85Test it: the count on this site

Get an email when these change. Save the Alpelisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 May 2019 · PIQRAY · NDA 212526 (FDA, Drugs@FDA)
European Union
27 Jul 2020 · Piqray · EMEA/H/C/004804 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Alpelisib
42
Phosphoinositide 3-kinase Inhibitor BYL719
7
alpelisib (BYL719)
3
Alpelisib 300 mg
2
Fulvestrant
2

Brand

Piqray
15
VIJOICE
3

Development codes

BYL719
54

Studies by the year they started

85 studies that test it; most in 2014 (11)

Studies that test Alpelisib, by start year
YearStudies
20101
20112
20126
20136
201411
20156
20165
20173
20182
20193
20204
202110
20229
20237
20246
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
43
Phase 2
42
Phase 3
8
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 38 · Other 47

Novartis Pharmaceuticals (34) · Columbia University (4) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2) · UNICANCER (2) · Pamela Munster (2) · Assistance Publique Hopitaux De Marseille (1)

Often tested with

Tested in the same studies.

Olaparib (6) · Ribociclib (4) · Trametinib (3) · Fulvestrant (3) · Letrozole (3) · Buparlisib (3) · Binimetinib (3) · Paclitaxel (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Alpelisib is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 4 most studied

New when their studies opened, with Alpelisib beside them; studies of each.

Reaching primary completion within a year · 13, 2 in phase 3

Studies that test Alpelisib, phase 3 first.

Studies

Open first, then newest update. How each study uses Alpelisib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 85

See all 85 studies that test Alpelisib →

Behind its US label · 2 — the studies the FDA label of PIQRAY, VIJOICE describes

From the Clinical Studies section of PIQRAY (2025-12), VIJOICE (2025-11), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 16 — no other medicine in its arm
Tested with established drugs · 25 — they are given beside it

Showing 20 of 25. See all 25 →

Tested in a combination · 44 — another drug in the study is under test too

Showing 20 of 44. See all 44 →

Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Alpelisib: atirmociclib 1 · Imlunestrant 1 · amcenestrant 1 · LSZ102 1

Beside supportive care · 8 — a supportive treatment or test is studied
One option of several · 6 — a test or a strategy chooses among drugs
As the comparator · 3 — what is tested is compared with Alpelisib
Observed · 16 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Codes

What other systems call Alpelisib · ClinicalTrials.gg INT006407

  • MeSH (NLM) C585539AlpelisibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 08W5N2C97QALPELISIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2169285Confirmed FDA, Wikidata
  • Wikidata Q27074391alpelisibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C94214AlpelisibOne source FDA
  • DrugBank DB12015One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion